A. The main purpose of this study is to find out if IRX-2 can help delay or prevent oral cancer from coming back after surgery. The study will also identify any side effects of IRX-2 and the drugs that are given with it.
A. If you are interested in possibly participating in the INSPIRE study, you should talk with your doctor as soon as possible, and definitely before your surgery is scheduled. The medications in the INSPIRE study have to be started before your surgery.
A. IRX-2 is an immunotherapy made up of substances naturally found in the body. Blood cells in donations from healthy donors are used to produce these substances (proteins), which may be lacking in certain oral cancer patients and that scientists believe are important and necessary for a properly functioning immune system. These substances may help activate (turn on) the immune system to fight cancer.
A. No. IRX-2 is an investigational (experimental) medicine that has not been approved in any country. The INSPIRE study is an important step to be performed to see if IRX-2 is helpful and safe.
A. The immune system can fight cancer, but in patients with oral cancer there are problems with the immune system. IRX-2 is designed to help fix these problems with the immune system to help its ability to fight cancer.
A. No. Two out of every 3 patients in the study will be treated with IRX-2. Patients receiving IRX-2 will be determined randomly (by chance). One out of every 3 patients in the study will be treated only with the drugs given with IRX-2.
A. No. IRX-2 is not approved or commercially available. The IRX-2 treatment is available only to people participating in the INSPIRE study or in other studies that may be started in the future.
A. No. IRX-2 is designed to strengthen your immune system to fight tiny pockets of cancer cells that could remain after surgery. For that reason, the initial doses of IRX-2 are given before surgery. Subsequent doses of IRX-2 are given after surgery as boosters.
A. Participating in the INSPIRE study should not mean a significant delay in your surgery date. Because your schedule may differ, feel free to discuss this concern with your doctor.
A. Patients in the study will be treated at intervals for 1 year. They will then be followed with occasional check-ups for a longer period of time.
A. The INSPIRE study is being led by IRX Therapeutics, Inc., the biotechnology company that invented the IRX-2 treatment, and by doctors who are experts in treating oral cancer.
A. A visiting nurse may come to your house to administer study treatment if you do not live near a study site. Alternatively, accommodations will be provided or reimbursed for people who have to travel long distances to a study site. Other travel and living costs can be paid depending on the distance you have to travel and the situation.
A. If you think you may want to participate in the INSPIRE study, you or your doctor can e-mail us at: INSPIRE@irxtherapeutics.com.